Atherogenic index of plasma is associated with the risk of myocardial infarction: a prospective cohort study

Background and aims The atherogenic index of plasma (AIP) has been confirmed as a contributor of cardiovascular disease. But few evidence on the longitudinal pattern of AIP during follow-up. This study aimed to explore the associations between baseline and long-term AIP with the risk of myocardial infarction (MI). Methods A total of 98 861 participants without MI at baseline were included from the Kailuan study. The baseline AIP was calculated as log (triglyceride/high-density lipoprotein cholesterol). The long-term AIP was calculated as the updated mean AIP and the number of visits with high AIP. The updated mean AIP was calculated as the mean of AIP from baseline to the first occurrence of MI or to the end of follow-up. The number of visits with high AIP was defined as higher than the cutoff value at the first three visits. Univariable and multivariable Cox proportional hazard models were used to determine the association between AIP and the risk of MI. Results During a median follow-up of 12.80 years, 1804 participants developed MI. The multivariable models revealed that elevated levels of baseline and updated mean AIP increased the risk of MI, compared with quartile 1 the HR in quartile 4 was 1.63 (95% CI, 1.41-1.88) and 1.59 (95% CI, 1.37-1.83), respectively. Compared to those without high AIP, the risk of individuals with three times was 1.94 (95% CI,1.55-2.45). Conclusions Elevated levels of both baseline and long-term AIP displayed a higher risk of MI. ### Competing Interest Statement The authors have declared no competing interest. ### Clinical Trial Not Applicable. ### Funding Statement None. ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: The study was performed according to the guidelines of the Helsinki Declaration and was approved by the Ethics Committee of Kailuan Hospital (approval number: 2006e05) and Beijing Tiantan Hospital (approval number: 2010-014-01). I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable. Yes The data and SAS code used in this current study are available from the corresponding authors on a reasonable request.